Anixa Biosciences Net Income
| ANIX Stock | USD 2.82 0.01 0.36% |
As of the 14th of February 2026, Anixa Biosciences shows the Mean Deviation of 3.61, standard deviation of 5.47, and Risk Adjusted Performance of (0.06). Anixa Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Anixa Biosciences Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -9.9 M | -10.4 M | |
| Net Loss | -9.9 M | -10.4 M | |
| Net Loss | -12.2 M | -12.8 M | |
| Net Loss | (0.30) | (0.32) | |
| Net Income Per E B T | 1.14 | 1.10 |
Anixa | Net Income | Build AI portfolio with Anixa Stock |
The evolution of Net Income for Anixa Biosciences provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Anixa Biosciences compares to historical norms and industry peers.
Latest Anixa Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Anixa Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Anixa Biosciences financial statement analysis. It represents the amount of money remaining after all of Anixa Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Anixa Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anixa Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (11.03 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Anixa Net Income Regression Statistics
| Arithmetic Mean | (8,931,163) | |
| Coefficient Of Variation | (44.69) | |
| Mean Deviation | 3,211,595 | |
| Median | (9,834,300) | |
| Standard Deviation | 3,991,480 | |
| Sample Variance | 15.9T | |
| Range | 12.6M | |
| R-Value | (0.59) | |
| Mean Square Error | 11T | |
| R-Squared | 0.35 | |
| Significance | 0.01 | |
| Slope | (469,378) | |
| Total Sum of Squares | 254.9T |
Anixa Net Income History
Other Fundumenentals of Anixa Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Anixa Biosciences Net Income component correlations
Anixa Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Anixa Biosciences is extremely important. It helps to project a fair market value of Anixa Stock properly, considering its historical fundamentals such as Net Income. Since Anixa Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Anixa Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Anixa Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anixa Biosciences. If investors know Anixa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anixa Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Anixa Biosciences's market price often diverges from its book value, the accounting figure shown on Anixa's balance sheet. Smart investors calculate Anixa Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Anixa Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Anixa Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anixa Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Anixa Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Anixa Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Anixa Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Anixa Biosciences.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Anixa Biosciences on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Anixa Biosciences or generate 0.0% return on investment in Anixa Biosciences over 90 days. Anixa Biosciences is related to or competes with Entera Bio, Inovio Pharmaceuticals, TuHURA Biosciences, Opus Genetics, Acumen Pharmaceuticals, VistaGen Therapeutics, and Seer. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in on... More
Anixa Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Anixa Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Anixa Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 40.89 | |||
| Value At Risk | (6.51) | |||
| Potential Upside | 8.98 |
Anixa Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anixa Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Anixa Biosciences' standard deviation. In reality, there are many statistical measures that can use Anixa Biosciences historical prices to predict the future Anixa Biosciences' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.31) |
Anixa Biosciences February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 3.61 | |||
| Coefficient Of Variation | (1,233) | |||
| Standard Deviation | 5.47 | |||
| Variance | 29.89 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.86) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 40.89 | |||
| Value At Risk | (6.51) | |||
| Potential Upside | 8.98 | |||
| Skewness | (0.92) | |||
| Kurtosis | 6.5 |
Anixa Biosciences Backtested Returns
Anixa Biosciences secures Sharpe Ratio (or Efficiency) of -0.0912, which signifies that the company had a -0.0912 % return per unit of risk over the last 3 months. Anixa Biosciences exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Anixa Biosciences' Standard Deviation of 5.47, mean deviation of 3.61, and Risk Adjusted Performance of (0.06) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.45, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Anixa Biosciences will likely underperform. At this point, Anixa Biosciences has a negative expected return of -0.5%. Please make sure to confirm Anixa Biosciences' coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if Anixa Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.74 |
Good predictability
Anixa Biosciences has good predictability. Overlapping area represents the amount of predictability between Anixa Biosciences time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Anixa Biosciences price movement. The serial correlation of 0.74 indicates that around 74.0% of current Anixa Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.74 | |
| Spearman Rank Test | 0.73 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Anixa Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Anixa Biosciences reported net income of (11.03 Million). This is 103.23% lower than that of the Biotechnology sector and 115.74% lower than that of the Health Care industry. The net income for all United States stocks is 101.93% higher than that of the company.
Anixa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anixa Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anixa Biosciences could also be used in its relative valuation, which is a method of valuing Anixa Biosciences by comparing valuation metrics of similar companies.Anixa Biosciences is currently under evaluation in net income category among its peers.
Anixa Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Anixa Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Anixa Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Anixa Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Anixa Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Anixa Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Anixa Biosciences' value.| Shares | Citadel Advisors Llc | 2025-06-30 | 70.9 K | Northern Trust Corp | 2025-06-30 | 66.7 K | Bank Of New York Mellon Corp | 2025-06-30 | 58.3 K | Corecap Advisors, Llc | 2025-06-30 | 46.8 K | Tyler-stone Wealth Management | 2025-06-30 | 42 K | Jane Street Group Llc | 2025-06-30 | 41.8 K | Hightower Advisors, Llc | 2025-06-30 | 38.1 K | Ci Private Wealth Llc | 2025-06-30 | 37.4 K | Prosperity Wealth Management Inc | 2025-06-30 | 36.5 K | Vanguard Group Inc | 2025-06-30 | 1.4 M | Laird Norton Tyee Trust Co | 2025-06-30 | 617.2 K |
Anixa Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 78.16 M | ||||
| Shares Outstanding | 33.38 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 16.04 % | ||||
| Number Of Shares Shorted | 1.19 M | ||||
| Price To Earning | (51.83) X | ||||
| Price To Book | 6.14 X | ||||
| Price To Sales | 481.54 X | ||||
| EBITDA | (11.7 M) | ||||
| Net Income | (11.03 M) | ||||
| Cash And Equivalents | 31.66 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 204 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.01 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (7.17 M) | ||||
| Short Ratio | 5.19 X | ||||
| Earnings Per Share | (0.34) X | ||||
| Target Price | 10.75 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 94.13 M | ||||
| Total Asset | 16.08 M | ||||
| Retained Earnings | (251.68 M) | ||||
| Working Capital | 13.92 M | ||||
| Current Asset | 10.38 M | ||||
| Current Liabilities | 1.36 M | ||||
| Net Asset | 16.08 M |
About Anixa Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anixa Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anixa Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anixa Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.